Lansforsakringar Fondforvaltning AB publ Reduces Holdings in Boston Scientific Corporation $BSX

Key Points

• Lansforsakringar Fondforvaltning AB publi reduced its holdings in Boston Scientific Corporation by 0.9%, owning approximately 859,556 shares valued at about $86.7 million following the sale of 7,527 shares.
• Brokerages have issued new price targets for Boston Scientific, with ratings including a "strong-buy" and an average price target of $117.50, indicating bullish sentiment among analysts.
• Insider trading activity includes significant stock sales by executives, with EVP Arthur C. Butcher and CEO Michael F. Mahoney selling 17,313 and 164,443 shares respectively, reflecting a 42.32% and 10.02% decrease in their ownership.

Lansforsakringar Fondforvaltning AB publ reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 0.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 859,556 shares of the medical equipment provider's stock after selling 7,527 shares during the period. Lansforsakringar Fondforvaltning AB publ owned approximately 0.06% of Boston Scientific worth $86,712,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of BSX. Colonial Trust Co SC grew its position in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV purchased a new position in Boston Scientific during the 4th quarter worth $25,000. Sunbeam Capital Management LLC purchased a new position in Boston Scientific during the 4th quarter worth $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific during the 1st quarter worth $27,000. Finally, Ameriflex Group Inc. purchased a new position in Boston Scientific during the 4th quarter worth $31,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BSX. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Needham & Company LLC reiterated a "buy" rating and issued a $115.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 28th. Leerink Partners started coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price objective for the company. UBS Group raised their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Finally, Morgan Stanley raised their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $117.50.

Boston Scientific Stock Performance

NYSE:BSX opened at $105.94 on Thursday. Boston Scientific Corporation has a 1-year low of $79.03 and a 1-year high of $108.94. The firm has a 50 day simple moving average of $104.36 and a 200-day simple moving average of $102.18. The firm has a market cap of $156.98 billion, a PE ratio of 63.06, a P/E/G ratio of 2.56 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm earned $0.62 earnings per share. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.